Aktuellt
SENASTE
Redeye comments on Isofol’s board proposing a liquidation of the company after considering different strategic alternatives. A liquidation and distribution of remaining funds was one of two potential scenarios we foresaw for the company following its failed AGENT trial. Our current base case of SEK1.0 per share derives from our estimate of Isofol’s cash position at the end of Q1 2023e. We will await the proposal's approval at an extraordinary general meeting as well as the company announcing a potential timeline and associated liquidation costs. We plan to update our fair value estimate once Isofol has communicated these pieces of information.
LÄS MER
